Get the Stockscreener App
1.09
2.83%
0.03
After Hours:
1.09
Agilon Health Inc stock is traded at $1.09, with a volume of 11.68M.
It is up +2.83% in the last 24 hours and down -13.49% over the past month.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
See More
Previous Close:
$1.06
Open:
$1.07
24h Volume:
11.68M
Relative Volume:
1.13
Market Cap:
$451.72M
Revenue:
$4.78B
Net Income/Loss:
$-284.68M
P/E Ratio:
-1.5797
EPS:
-0.69
Net Cash Flow:
$-184.84M
1W Performance:
+9.00%
1M Performance:
-13.49%
6M Performance:
-79.66%
1Y Performance:
-65.40%
1-Day Range:
$1.02
$1.09
1-Week Range:
$1.00
$1.18
52-Week Range:
$0.71
$5.77
Agilon Health Inc Stock (AGL) Company Profile
Name
Agilon Health Inc
Sector
Industry
Phone
562-256-3800
Address
6210 E HWY 290, AUSTIN
Compare AGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGL
Agilon Health Inc
|
1.09 | 439.29M | 4.78B | -284.68M | -184.84M | -0.69 |
|
HCA
Hca Healthcare Inc
|
426.27 | 102.39B | 72.70B | 6.88B | 7.29B | 23.81 |
|
THC
Tenet Healthcare Corp
|
200.48 | 18.10B | 20.69B | 2.40B | 1.55B | 15.62 |
|
FMS
Fresenius Medical Care Ag Adr
|
27.07 | 15.74B | 21.23B | 924.30M | 2.22B | 1.2272 |
|
EHC
Encompass Health Corp
|
124.40 | 12.61B | 5.51B | 494.70M | 386.40M | 4.84 |
|
UHS
Universal Health Services Inc
|
205.20 | 13.35B | 16.08B | 1.20B | 1.06B | 17.82 |
Agilon Health Inc Stock (AGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Aug-06-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-25-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-08-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-10-25 | Upgrade | Citigroup | Sell → Neutral |
| Jan-10-25 | Initiated | Needham | Hold |
| Dec-16-24 | Initiated | Macquarie | Neutral |
| Dec-11-24 | Initiated | Bernstein | Mkt Perform |
| Nov-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-30-24 | Downgrade | Citigroup | Neutral → Sell |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Underperform |
| May-30-24 | Initiated | Robert W. Baird | Neutral |
| Apr-22-24 | Initiated | Citigroup | Neutral |
| Mar-06-24 | Initiated | Barclays | Underweight |
| Feb-26-24 | Downgrade | Jefferies | Buy → Hold |
| Feb-26-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jan-08-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-24 | Downgrade | Stifel | Buy → Hold |
| Jan-08-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-05-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-06-23 | Initiated | JMP Securities | Mkt Outperform |
| Nov-21-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-20-23 | Initiated | The Benchmark Company | Buy |
| Jun-13-23 | Initiated | Evercore ISI | In-line |
| Dec-09-22 | Initiated | Stifel | Buy |
| Sep-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-22 | Initiated | Goldman | Buy |
| Sep-07-22 | Resumed | Truist | Buy |
| Jun-24-22 | Initiated | BTIG Research | Neutral |
| Mar-30-22 | Initiated | Guggenheim | Buy |
| Oct-20-21 | Initiated | Jefferies | Buy |
| Sep-27-21 | Initiated | SVB Leerink | Outperform |
| Sep-10-21 | Initiated | Cowen | Outperform |
| May-11-21 | Initiated | William Blair | Outperform |
| May-10-21 | Initiated | BofA Securities | Buy |
| May-10-21 | Initiated | Deutsche Bank | Buy |
| May-10-21 | Initiated | Goldman | Buy |
| May-10-21 | Initiated | JP Morgan | Overweight |
| May-10-21 | Initiated | Truist | Buy |
| May-10-21 | Initiated | Wells Fargo | Overweight |
| May-10-21 | Initiated | Wolfe Research | Outperform |
View All
Agilon Health Inc Stock (AGL) Latest News
Agilon Health's (AGL) "Sell (E+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
New Strong Sell Stocks for October 8th - sharewise.com
What analysts say about agilon health inc stockInstitutional Holding Changes & Capital Planning and Optimization - earlytimes.in
agilon health Sets Date to Report Third Quarter 2025 Financial Results - The Joplin Globe
How to build a dashboard for agilon health inc. stockJuly 2025 Momentum & Expert Curated Trade Setup Alerts - newser.com
Price action breakdown for agilon health inc.Weekly Gains Report & Entry Point Strategy Guides - newser.com
Will agilon health inc. stock rally after Fed decisionsQuarterly Portfolio Review & Risk Controlled Daily Plans - newser.com
Can agilon health inc. stock deliver surprise earnings beatTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
Why agilon health inc. stock appeals to dividend investorsChart Signals & Reliable Entry Point Alerts - newser.com
How agilon health inc. stock benefits from digital adoptionJuly 2025 Setups & Weekly Breakout Stock Alerts - newser.com
Is agilon health inc. stock poised for growthJuly 2025 News Drivers & Risk Adjusted Swing Trade Ideas - newser.com
How to use Fibonacci retracement on agilon health inc.July 2025 Intraday Action & Capital Efficient Trading Techniques - newser.com
agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know - The Globe and Mail
Health Check: How Prudently Does agilon health (NYSE:AGL) Use Debt? - Sahm
New Strong Sell Stocks for October 1st - The Globe and Mail
AGILON INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
agilon health at Jefferies 2025: Strategic Shift to Profitability By Investing.com - Investing.com Canada
Is it too late to sell agilon health inc.2025 Dividend Review & Fast Gaining Stock Strategy Reports - newser.com
Benchmark maintains Buy rating on agilon health stock amid 2026 outlook By Investing.com - Investing.com South Africa
Benchmark maintains Buy rating on agilon health stock amid 2026 outlook - Investing.com Australia
Will agilon health inc. outperform the marketTrade Exit Summary & Daily Growth Stock Tips - newser.com
Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of agilon health, inc.AGL - FinancialContent
Agilon Health, Inc. (NYSE:AGL) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Agilon Health (AGL): Buy, Sell, Or Hold Post Q2 Earnings? - Barchart.com
agilon health (AGL): Buy, Sell, or Hold Post Q2 Earnings? - The Globe and Mail
agilon health, inc. (AGL) Investor Outlook: Exploring a 31% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Agilon Health (NYSE:AGL) Stock Price Up 7.6%Here's What Happened - MarketBeat
Buybacks Report: Is agilon health inc forming a double bottomChart Signals & Low Drawdown Trading Strategies - خودرو بانک
MACD Signal: Can agilon health inc stock double in the next yearQuarterly Growth Report & Smart Allocation Stock Reports - خودرو بانک
Risk Analysis: Can agilon health inc stock double in the next yearJuly 2025 EndofMonth & Reliable Price Breakout Signals - خودرو بانک
Risk Off: Is agilon health inc stock a buy or sellJuly 2025 Chart Watch & High Accuracy Trade Alerts - خودرو بانک
Agilon Health Inc Stock (AGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agilon Health Inc Stock (AGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Battaglia Silvana | Director |
Dec 11 '24 |
Buy |
2.01 |
25,062 |
50,269 |
66,144 |
| MCKENZIE DIANA | Director |
Nov 25 '24 |
Buy |
2.28 |
12,500 |
28,474 |
51,319 |
| MCKENZIE DIANA | Director |
Dec 09 '24 |
Buy |
2.20 |
7,500 |
16,489 |
58,819 |
| Wulf John William | Director |
Dec 05 '24 |
Buy |
2.18 |
45,000 |
98,145 |
206,133 |
0.52%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):